parp inhibitors for early, brca-mutant breast cancer - medpage today
Published 3 years ago • 41 plays • Length 13:20Download video MP4
Download video MP3
Similar videos
-
3:14
parp inhibitor staves off recurrence in early brca-mutant breast cancer - medpage today
-
4:19
parp inhibitor active in ovarian cancer
-
2:36
sabcs: parp inhibitor data called 'spectacular'
-
3:26
better pros with niraparib maintenance in ovarian cancer - medpage today
-
1:17
dr. traina on parp inhibition in brca-mutated breast cancer
-
7:04
testing for brca germline mutations in the clinic and the mechanism of action of parp inhibitors
-
48:28
parp inhibitors for the treatment & prevention of hereditary breast & ovarian cancer
-
3:30
2020 in review: olaparib & rucaparib, fda approval | ask a prostate expert, mark scholz, md
-
27:25
opportunities and challenges in early breast cancer: do parp inhibitors have a role?
-
3:58
brca breast cancer: the advent of parp inhibitors
-
2:15
parp inhibitors in metastatic breast cancer: where are we now?
-
2:21
a study of talazoparib in somatic brca1/2 mutant mbc identified by cfdna or tumor tissue genotyping
-
2:47
talave: induction talazoparib with parp inhibition in breast cancer
-
0:27
parp inhibitors #short
-
5:18
parp inhibitors for brca-mutated tnbc
-
6:20
parp inhibitors for brca-mutated tnbc
-
3:56
parp inhibitors: activity in brca1 versus brca2 altered mcrpc
-
1:58
discussing targeted treatment with parp inhibitors for brca-mutant patients across tumor types
-
5:40
parp inhibitor combo shows early promise for patients with and without brca mutations